Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANS.NRIZ: Nitazoxanide, Ribavirin, Ivermectin, and Zinc in COVID-19
NCT04392427Phase 3Unknown
- Sponsor
- Mansoura University
- Start
- Oct 2020
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nitazoxanide, ribavirin, ivermectin and zinc in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Mansoura University. Primary endpoint: Negative test result for COVID-19 at 2 years. Status: unknown.
02
Drugs
nitazoxanideribavirinivermectinzinc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04392427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392427.